Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
19:01:13 EDT Fri 03 May 2024
Enter Symbol
or Name
USA
CA



Q:BPTH - BIO-PATH HOLDINGS INC - http://www.biopathholdings.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
BPTH - Q0.12.60·2.760.22.61-0.05-1.9275.46868002.55  2.82  2.5544.80  2.3517:52:22Apr 1915 min RT 2¢

Recent Trades - Last 10 of 800
Time ETExPriceChangeVolume
17:52:22Q2.60-0.0624
17:50:22Q2.60-0.06300
17:30:05Q2.60-0.06100
17:16:47Q2.700.0410
17:15:44Q2.700.0420
16:00:01Q2.61-0.0525
16:00:01Q2.61-0.0515
16:00:01Q2.61-0.0575
16:00:01Q2.61-0.05160
16:00:01Q2.61-0.0519

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-19 12:14U:BPTHNews ReleaseBio-Path Holdings, Inc. Announces Closing of $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
2024-04-18 13:58U:BPTHNews ReleaseBio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
2024-04-18 07:00U:BPTHNews ReleaseBio-Path Holdings Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients
2024-04-15 07:00U:BPTHNews ReleaseBio-Path Holdings Expands Global Patent Portfolio
2024-04-02 07:00U:BPTHNews ReleaseBio-Path Holdings Provides 2024 Clinical and Operational Update
2024-03-27 16:44U:BPTHNews ReleaseStonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q4 23
2024-03-08 07:00U:BPTHNews ReleaseBio-Path Holdings Reports Full Year 2023 Financial Results
2024-03-01 07:00U:BPTHNews ReleaseBio-Path Holdings to Announce Fourth Quarter and Full Year 2023 Financial Results on March 8, 2024
2024-02-21 07:00U:BPTHNews ReleaseBio-Path Holdings Announces 1-for-20 Reverse Stock Split
2024-01-10 07:00U:BPTHNews ReleaseBio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory/Relapsed Lymphoma and Refractory/Relapsed Chronic Lymphocytic Leukemia Patients
2023-12-14 07:00U:BPTHNews ReleaseBio-Path Holdings Successfully Completes First Dose Cohort of Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia
2023-11-15 07:00U:BPTHNews ReleaseBio-Path Holdings Reports Third Quarter 2023 Financial Results
2023-11-08 07:00U:BPTHNews ReleaseBio-Path Holdings to Announce Third Quarter 2023 Financial Results on November 15, 2023
2023-10-24 07:00U:BPTHNews ReleaseBio-Path Holdings to Host Virtual Key Opinion Leader Event to Discuss Prexigebersen and Advances in the Treatment Landscape for Acute Myeloid Leukemia
2023-09-08 16:01U:BPTHNews ReleaseBio-Path Holdings to Present at H.C. Wainwright 25th Annual Global Investment Conference
2023-08-30 17:12U:BPTHNews ReleaseStonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q2 23
2023-08-15 07:00U:BPTHNews ReleaseBio-Path Holdings Reports Second Quarter 2023 Financial Results
2023-08-08 07:00U:BPTHNews ReleaseBio-Path Holdings to Announce Second Quarter 2023 Financial Results on August 15, 2023
2023-08-03 08:23U:BPTHNews ReleaseBio-Path Holdings, Inc. Announces Pricing of $2.1 Million Public Offering
2023-08-01 07:00U:BPTHNews ReleaseBio-Path Holdings Announces Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia